Planview Reports Record Q2 and H1 2023, Continues Momentum Amid Challenging Economic Landscape
Planview, the leading platform for digital connected work from portfolio planning to delivery, announced today record annual recurring revenue (ARR) and bookings in Q2, continuing strong momentum and growth in 2023. ACV Bookings for Q2 and the first half of the year were at a record high approaching 30% growth year-over-year (YoY), driven by both new customer additions and customer expansions across financial services, automotive, and healthcare. At the close of H1 2023, Planview is outpacing its forecasts on several key measures, including bookings, retention, and ARR this year. These results are driven by significant demand from customers who require data-driven insights to effectively prioritize initiatives, allocate capital and utilize resources across digital transformation efforts.
“The macroenvironment continues to pose challenges for digital transformation efforts in companies around the world. Organizations are faced with inflation, changing customer expectations, and more conservative budgets,” said Razat Gaurav, CEO at Planview. “At the same time, they must continue to drive forward transformation initiatives to adapt and achieve key business outcomes. Planview’s connected solution is uniquely positioned to give leaders and organizations the data-driven alignment, transparency, and visibility to make critical prioritization decisions, enabling companies to increase productivity, improve time-to-market, and de-risk strategic bets.”
H1 2023 Highlights
- Strong ACV bookings growth for the first half of 2023, approaching 30% growth YoY
- Significant improvements to Retention through first half of 2023, +100bps improvement to Net Retention YoY
- Recurring Revenue grew 13% during the first half of 2023 YoY
- Added over 126 net new customers
- Grew total active users for University of Planview by 29% quarter-over-quarter
Strong New Logo and Customer Momentum
Planview’s outperformance and profitable growth has been driven by new customer wins and expansions. New and notable customers who partnered or significantly expanded their footprint with Planview include AT&T, Axcelis Technologies, Bausch + Lomb, Baylor Scott & White Health, CellCarta, ChristianaCare, Commonwealth Bank of Australia, Corewell Health, Ecopetrol Group, Foodstuffs, Ford Motor Company, Inland Empire Health Plan, LandSure Systems, Mitsubishi UFJ Financial Group, New York Life Insurance Company, Omnicell, OneSavings Bank, PagoNxt, Pladis Global, Schaeffler Group, Schwab, Sherwin-Williams, Sun Life Financial, Transport for NSW, Tronox Holdings, Vanguard Group, Vonage, and Voya.
Industry Leadership & Product Innovation
Key milestones that support continued customer success and the company's strong growth:
- Showcased new Generative AI based assistant at the Reuters Momentum AI Summit.
- Released the landmark 2023 Project to Product State of the Industry Report, which revealed that 40% of Digital Innovation work is being wasted today.
- Recognized for the second consecutive year as a leader in the 2023 Gartner® Magic Quadrant™ for Strategic Portfolio Management. The company was positioned furthest for Completeness of Vision.
- Expanded its global footprint with growing teams in North America, EMEA, Israel and India, with a focus on Artificial Intelligence (AI), Data Science, R&D, Premium Support, Managed Services, InfoSec, and Partners/Strategic Alliances.
- Increased its global partner ecosystem with the additions of UiPath and NTT Data, focused on delivering Value Stream Management capabilities.
- Dramatically expanded its partnership with AWS, including achievement of AWS ISV Accelerate Program membership and the launch of five Planview solutions in the AWS Marketplace.
- Increased in monthly active users by 15% YoY for leading products.
Planview is continuing to invest heavily in product innovation, customer success and go-to-market, building a foundation for continued customer satisfaction and growth in 2023 and beyond.
About Planview
Planview has one mission: to build the future of connected work, from ideas to impact. Planview helps organizations accelerate the achievement of what matters most, supporting our customers from need to speed, from passion to progress, and from overhead to optimization. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers globally, including 59 of the Fortune 100. Planview empowers enterprises to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic initiatives deliver the desired business outcomes. Learn more about our portfolio at planview.com, and connect with us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720450990/en/
Contact information
Media Relations for Planview
Natalie Reina
Director of Corp Comms
956-878-9176
natalie.reina@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Begins Commercialization of BYOOVIZ ® , Biosimilar to Lucentis (Ranibizumab), in Europe2.1.2026 09:00:00 EET | Press release
Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries. “This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizumab) and the newly launched OBODENCE (denosumab) and XBRYK (denosumab) in Europe, we will continue on our journey to become a fully integrated biopharmaceutical company with end-to-end capabilities from development to commercialization,” said Antonio Rito, Vice President and Head of Europe, at Samsung Bioepis. “We will work closely with payers and healthcare professionals to e
Cessna Citation Ascend Enters Into Service, Redefining Performance and Cabin Experience in the Midsize Business Jet Market31.12.2025 16:00:00 EET | Press release
The Cessna Citation Ascend achieved a major milestone as the first retail customer took delivery of the midsize business jet on Tuesday, December 30, marking the aircraft’s entry into service. Announced in 2023 the aircraft boasts an entirely new cockpit, improved performance and a luxurious flat floor cabin. The Citation Ascend received type certification from the Federal Aviation Administration (FAA) in November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231586042/en/ Cessna Citation Ascend enters into service, redefining performance and cabin experience in the midsize business jet market. (Photo credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The first Citation Ascend delivery underscores Textron Aviation’s commitment to redefining the midsize segment with an aircraft that blends innovation, efficiency and unmatch
Aster Guardians Global Nursing Award 2026 Worth $250,000 Extends Deadline Till 11 th January 202631.12.2025 15:08:00 EET | Press release
The Aster Guardians Global Nursing Award 2026, an initiative from Aster DM Healthcare – a leading integrated healthcare provider, has announced the extension of its deadline to January 11, 2026. The awards have already received over 134,000 registrations from 214 countries, highlighting its growing global reach and recognition among nurses worldwide. Nurses from around the world can submit their nominations through the dedicated platform at www.asterguardians.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231986766/en/ Aster Guardians Global Nursing Award worth USD 250,000 (Photo: AETOSWire) This year, the prestigious award will be hosted in New Delhi, India, celebrating nursing excellence on a truly global stage. The fourth edition of the awards were held in Dubai, UAE where Nurse Naomi Oyoe Ohene Oti was honoured as the winner for her transformative work in cancer care and education that has shaped oncology nursing
Tecnotree Included as a Representative Provider in Gartner ® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation31.12.2025 12:59:00 EET | Press release
Tecnotree, a global digital platform and services provider for communications service providers (CSPs), today announced that it has been referenced as a Representative Provider alongside Google, Anthropic, Dropzone AI, DRUID, Palo Alto Networks, and Pegasystems in the Gartner® Innovation Insight: “AI SOC Agents Accelerate CSP SecOps Transformation,” published in December 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231210303/en/ Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation The Gartner Innovation Insight examines the emerging role of AI-driven Security Operations Centre (SOC) agents in CSP environments, outlining how these agents are used to automate and augment security operations across signalling, core networks, RAN, Open RAN, and roaming domains. The research discusses use cases such as alert triage, investigation support, thr
UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy30.12.2025 16:15:00 EET | Press release
Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone positions Medcare among the first private healthcare providers worldwide to offer this innovative treatment to an older international patient, overcoming previous age and weight limitations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251230695275/en/ World's first international patient, who received intrathecal gene therapy at Medcare Royal Hospital in Dubai, UAE, along with parents, and the hospital team. (Photo: AETOSWire) SMA is a rare neuromuscular disorder that progressively weakens muscles responsible for movement and breathing. This newly licensed one-time therapy addresses the root genetic cause by delivering a functional SMN1 gene. For Hulus, whose daily routine earlier depended on intensive physiotherapy and hydroth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
